Stocks TelegraphStocks Telegraph
Stock Ideas

Pre-Market Surge Sustained For C4 Therapeutics (CCCC) Stock

By Fahim Awan
Published On December 13, 2023 1:56 PM UTC
Pre-Market Surge Sustained For C4 Therapeutics (CCCC) Stock

C4 Therapeutics, Inc. (NASDAQ: CCCC) shares are evidently sustaining the upward momentum initiated on Tuesday. Presently, C4 Therapeutics stock exhibits a 17.09% surge, reaching $2.74 in the pre-market session as of the last check. In the previous trading session, CCCC stock observed a noteworthy ascent of 98.31%, concluding the session at $2.34. This notable upswing ensued subsequent to the establishment of a strategic business collaboration.

C4 Therapeutics (CCCC) has formalized an exclusive license and collaboration accord with Merck, known as MSD beyond the confines of the U.S. and Canada. The focal point of this agreement is the development of degrader-antibody conjugates (DACs), an emerging modality tailored to selectively combat and neutralize pathogenic proteins within cancer cells.

The partnership between C4 Therapeutics and Merck is poised to innovate within the expanding domain of antibody-drug conjugates, exploring the synergies between the catalytic efficiency, potency, target specificity, and durability of degraders, and the precise binding and delivery capabilities of antibodies. Leveraging the robust TORPEDO platform in tandem with Merck’s expertise in antibody-drug conjugation, the collaboration aims to engineer groundbreaking medicines capable of transformative impacts on patients’ lives.

In adherence to the agreement’s stipulations, C4T is set to receive a $10 million upfront payment. The collaborative efforts will initially be directed towards developing DACs targeting an undisclosed oncology target exclusive to the partnership. For DACs associated with this initial target, C4T stands to receive milestone payments amounting to approximately $600 million, alongside tiered royalties on future sales.

Additionally, the agreement grants Merck the option to extend the collaboration to encompass three additional exclusive targets, potentially resulting in option exercise payments, as well as subsequent milestones and royalties. If Merck chooses to exercise all available options, C4T stands to gain potential payments totaling up to approximately $2.5 billion throughout the entire collaboration.

This collaboration represents a fusion of Merck’s substantial expertise in biological chemistry with C4 Therapeutics’ pioneering protein degradation technology, fostering the exploration of novel avenues to advance the realm of targeted medicine.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph